Topic: drug reimbursement
Rival PARP inhibitors by GSK and AstraZeneca-Merck already have their own NICE backing, though neither of the three is on routine coverage.
Vertex hasn't been able to reach a deal for cystic fibrosis drug access in England, but in neighbor Scotland, the company has struck a five-year agreement.
New CMS rules have removed some restrictions on healthcare providers that could in turn boost uptake of Gilead's and Novartis' CAR-T drugs.
Contradicting analysts' observations, Novartis CEO dubbed Zolgensma “one of the most successful launches from an access standpoint in rare diseases.”
England’s cost watchdogs won’t get behind AZ blockbuster Tagrisso. But in a change of events, they’re instead backing a Pfizer challenger.
Sanofi and Regeneron’s Libtayo is two for two in the last two days—at winning over key European regulatory and reimbursement bodies, that is.
Pfizer and Astellas’ Xtandi lost its bid to expand to the U.K. market after an English watchdog said it was ineffective in extending survival over placebo.
AstraZeneca’s Imfinzi is working to grab sales in a rival-free sector of the lung cancer market, and England’s cost watchdogs just gave it a boost.
BioMarin and NICE have been negotiating for a year, but that hasn’t helped the company secure reimbursement for its Batten disease drug.
Looks like the third time was a charm for Roche’s Perjeta when it comes to postsurgery treatment of HER2-positive breast cancer.